Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Co.'s pipeline consists of: its primary product candidate, Buntanetap, which is an orally administered drug being developed for chronic indications such as AD and PD; ANVS405, which is an intravenous drug being developed for acute indications, and is focused on protecting the brain after TBI and/or stroke; as well as ANVS301, which is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. We show 8 historical shares outstanding datapoints in our coverage of ANVS's shares outstanding history.
Understanding the changing numbers of ANVS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANVS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANVS by allowing them to research ANVS shares outstanding history
as well as any other stock in our coverage universe. |
Free ANVS Email Alerts:
Video: Shares Outstanding Importance
